Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics.
Working in the Division of Cancer Epigenetics Unit, his current work is aimed at investigating germline epigenetic alterations as a mechanism for carcinogenesis funded by Breast Cancer Now and Cancer Research UK. He was awarded the British Association of Cancer Research Translational Researcher Award in 2011.
Current research is aimed at investigating epigenetic alterations as a mechanism for carcinogenesis, including projects to define tumour subgroups, identification of biomarkers for cancer risk or prognosis in breast and ovarian cancer and investigating the mechanism of transcriptional regulation by DNA methylation outside of the classical promoter CpG Island. Recent work has focused on the hypothesis that epigenetic variation may be a driver of cancer risk whether by inherent constitutional variation or as a mediator of other cancer risk factors.